Skip to main content

Table 2 Geometric mean ratios of rifabutin and 25-O-desacetylrifabutin parameters with and without antiretroviral therapy

From: Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy

 

GMR (90% CI)

 

RBT 150 mg tiw with RBT 300 mg daily

RBT 150 mg tiw with RBT 150 mg daily

RBT 150 mg daily with RBT 300 mg daily

AUC0–24

0.8 (0.7 – 0.9)

0.4 (0.5 – 0.5)

1.6 (1.4 – 1.9)

AUC0–48*

0.6 (0.5 – 0.7)

0.4 (0.4 – 0.4)

n/a

Cmax(ng/mL)

0.5 (0.4 – 0.6)

0.5 (0.5 – 0.6)

1.0 (0.9 – 1.0)

C0(ng/mL)

0.7 (0.5 – 0.9)

0.2 (0.1 – 0.3)

3.4 (3.7 – 3.1)

Cmin24h(ng/mL)

1.2 (1.0 – 1.4)

0.5 (0.4 – 0.5)

2.7 (2.2 – 3.2)

  1. *calculated by 2 times the AUC0–24 for the RBT 300 mg daily and RBT 150 mg daily arms.
  2. n/a – Not applicable.
  3. GMR – Geometric mean ratio.
  4. 90% Cl – 90% confidence interval.
  5. RBT 150 mg tiw – rifabutin dose of 150 mg three times per week (tiw) in combination with lopinavir/ritonavir based ART and isoniazid.
  6. RBT 150 mg daily – rifabutin dose of 150 mg daily in combination with lopinavir/ritonavir based ART and isoniazid.
  7. RBT 300 mg daily – rifabutin dose of 300 mg daily in combination with isoniazid.
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us